Published online by Cambridge University Press: 15 April 2020
Comparative study of the blood lipid spectrum changes in first-episode schizophrenia patients treated with risperidone and haloperidol.
68 patients with first-episode schizophrenia (average age 24,9 years) and 20 age-matched normal controls were investigated. All patients had PANSS total score not less than 80 points. The patients were divided in two groups of 34 persons in each group: treated with haloperidol and risperidone. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), non-high-density lipoprotein cholesterol (non-HDL), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), lipoprotein(a) (Lp(a)) levels were determined in serum before treatment and after 8 weeks of therapy.
Before the treatment TC, LDL, non-HDL, apoB, Lp(a) levels were authentically higher, but HDL level was lower. After treatment with risperidone and haloperidol HDL and apoA1 levels were increased. In patient group treated with risperidone TC, LDL, non-HDL, apoB, Lp(a) levels did not authentically change after 8 weeks. After treatment with haloperidol TC, LDL, non- HDL, apoB, Lp(a) levels were decreased.
Changes of blood lipid spectrum in first-episode schizophrenia patients were discovered. It was established changes of lipid spectrum in patients treated with risperidone and haloperidol. Haloperidol was noticed to positively influence on blood lipid spectrum in first-episode schizophrenia patients.
Comments
No Comments have been published for this article.